<?xml version="1.0" encoding="UTF-8"?>
<sect1 id="ch0017s0001" role="Heading">
   <sect1info>
      <risinfo>
         <risprev>sect1.9781071643624.ch0017s0009</risprev>
         <riscurrent>sect1.9781071643624.ch0017s0001</riscurrent>
         <risnext>sect1.9781071643624.ch0017s0002</risnext>
         <booktitle>Diagnostic Interviewing</booktitle>
         <isbn>9781071643624</isbn>
         <chapternumber>17</chapternumber>
         <chapterid>ch0017</chapterid>
         <chaptertitle>15.Â Substance Use Disorders</chaptertitle>
         <authorgroup>
            <author>
               <personname>
                  <firstname>Daniel L.</firstname>
                  <surname>Segal</surname>
               </personname>
            </author>
         </authorgroup>
         <publisher>
            <publishername>Springer US</publishername>
         </publisher>
         <pubdate>2025</pubdate>
      </risinfo>
      <primaryauthor>
         <personname>
            <firstname>Daniel L.</firstname>
            <surname>Segal</surname>
         </personname>
      </primaryauthor>
   </sect1info>
   <title>Description of the Disorders</title>
   <para role="Para">Substance use and associated<indexterm significance="normal">
         <primary>associated</primary>
      </indexterm> problems are pervasive and costly. According to the 2023 United States National Survey on Drug Use and Health, 48.7 million people aged 12 and older met the criteria for an SUD in the past year, of whom 29.7 million met the criteria for alcohol use disorder, and 27.2 million met the criteria for an illicit drug use disorder (Substance Abuse and Mental Health Services Administration (SAMHSA), <emphasis role="CitationRef">
         <phrase>2023</phrase>
      </emphasis>). There are serious<indexterm significance="normal">
         <primary>serious</primary>
      </indexterm>public health and economic consequences associated with substance use, including co-occurring psychiatric diagnoses, health-compromising behaviors (e. g., drug injection; Berry &amp; Johnson,<emphasis role="CitationRef">
         <phrase>2019</phrase>
      </emphasis>), unemployment (Nolte-Troha et al., <emphasis role="CitationRef">
         <phrase>2023</phrase>
      </emphasis>), and homelessness (Giano et al., <emphasis role="CitationRef">
         <phrase>2020</phrase>
      </emphasis>). In 2021, there were 106,999 drug overdose deaths in the United States, most of which involved synthetic opioids (Centers for Disease Control and Prevention, <emphasis role="CitationRef">
         <phrase>2020</phrase>
      </emphasis>). The 7.5-fold increase in overdose deaths between 2015 and 2021 is also due to the increase in psychostimulant-related deaths (e. g., methamphetamine) (NIDA,<emphasis role="CitationRef">
         <phrase>2023</phrase>
      </emphasis>). Recovery from an SUD often requires multiple treatment attempts, and treatment dropout rates are ~30%, with significant heterogeneity across racial and socioeconomic backgrounds (Lappan et al., <emphasis role="CitationRef">
         <phrase>2020</phrase>
      </emphasis>).</para>
</sect1>